Crucial updates on Fatty Liver disease - EASL 2023 - steatotic liver disease, MASLD, and MetALD
In this update video, we'll be discussing the latest research from EASL 2023 on fatty liver disease (FLD) nomenclature, including steatotic liver disease (SLD), Metabolic dysfunction associated SLD (MASLD) and Metabolic dysfunction with alcohol-associated SLD (MetALD).
If you're looking for information on fatty liver disease (FLD), then you'll want to watch this video! These are very important updates that you need to be aware of if you have or are at risk of developing Fatty Liver disease. We're going to discuss some of the most important updates on fatty liver disease - EASL 2023. We'll cover steatotic liver disease, MASLD, and MetALD, and provide some crucial information you need to know about these conditions.
MASLD has become a significant public health concern globally, closely associated with the rising prevalence of obesity and metabolic disorders. It is now recognized as the most common chronic liver disease worldwide.
It is strongly associated with metabolic disorders such as obesity, insulin resistance, dyslipidemia, and type 2 diabetes.
MAFLD occurs when there is an abnormal buildup of fat in the liver cells (hepatocytes). The excess fat, primarily triglycerides, accumulates due to an imbalance between the uptake, synthesis, and export of fatty acids in the liver.
Metabolic Dysfunction: MAFLD is closely related to metabolic dysfunction, which refers to a cluster of conditions that disrupt normal metabolic processes in the body. These include insulin resistance, impaired glucose metabolism, dyslipidemia (abnormal lipid levels), and obesity. These metabolic abnormalities contribute to the development and progression of MAFLD.
MAFLD encompasses a spectrum of liver conditions, ranging from simple steatosis (fatty liver) to non-alcoholic steatohepatitis (MASH), which involves liver inflammation and can progress to liver fibrosis, cirrhosis, and even liver cancer in severe cases.
The diagnosis of MAFLD involves assessing the presence of hepatic steatosis (fat accumulation) in the liver using imaging techniques such as ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI). Additionally, other causes of liver disease (such as excessive alcohol consumption, and viral hepatitis) must be ruled out.
The primary treatment for MAFLD involves lifestyle modifications, including weight loss, regular exercise, and a healthy diet. These changes can help improve metabolic health, reduce liver fat, and prevent disease progression. In some cases, medication may be prescribed to manage specific metabolic abnormalities.